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The important co-existence of spondylarthritis (SpA) and inflammatory bowel disease (IBD) 
within the same individual suggests common etiopathogenic mechanisms. This is supported 
by intriguing similarities between both diseases at the subclinical and molecular level. The 
recent advances in IBD genetics have led to the identification of common pathways involved 
in both IBD and SpA, including bacterial recognition and ER stress. This offers the 
opportunity to develop potential new therapeutic strategies for both diseases. Transgenic 
animals which develop both joint and gut inflammation (like the TNF
∆ARE
 mice and the HLA-
B27 transgenic rats) are a very useful tool to test such novel therapeutics and to get further 
mechanistic insight into the pathogenetic link between SpA and IBD. 
This review will focus on the recent scientific progress in our understanding of the link 





















The extraintestinal manifestations of inflammatory bowel disease (IBD) include peripheral 
and axial arthropathy in 20% of patients, skin involvement in 20% of patients, uveitis in 8% 
and liver disease in 6% of patients. The arthropathy observed in IBD belongs to the concept of 
spondylarthropathy (SpA) and includes a transient, migratory and mostly non-deforming 
arthritis and/or an inflammatory back pain associated with sacroiliitis and spondylitis. On the 
other hand, extra-articular manifestations of SpA include IBD in 20% of patients, psoriasis in 
20% of patients and uveitis in 51% of patients. Characteristic for gut, joint, skin and eye 
disease is the well-proven effect of TNF-α blockers, suggesting a central role of TNF-α in 
these immune-mediated inflammatory diseases. 
 
Besides the important coincidence of IBD and SpA, an intriguing link between both disorders 
is found at the subclinical level. On the one hand, asymptomatic sacroiliitis is present on 
radiography in 16% of patients with IBD. However, when using MRI to detect sacroiliitis, the 
prevalence will probably be much higher, as it has been demonstrated that the clinical stage of 
inflammation is preceded by abnormalities on MRI including oedema of the cartilaginous 
portion of the sacroiliac joint and fat deposition in the subchondral bone marrow followed by 
the well-known erosions of joint facets and narrowing of joint space  [1]. On the other hand, 
subclinical gut inflammation has been described in 60% of patients with SpA including in 
25% of patients a chronic gut inflammation with increased risk for the development of overt 
IBD [2]. 
 
Based on recent literature, this review aims to give an overview of the processes involved in 
both joint and gut inflammation. 
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 mouse model is characterized by a 69 base pair deletion of TNF-α AU-rich 
elements from the mouse genome leading to steady-state increased TNF-α mRNA levels  in 
hematopoietic and stromal cells as well as a diminished translational silencing of the TNF-α 
mRNA. Starting at the age of 5 weeks, the animals spontaneously develop an inflammatory 
disease characterized by CD-like chronic ileitis and SpA-like sacroiliitis, achilles tendon 
enthesitis and peripheral arthritis. Therefore, this is an ideal model to study the relationship 
between CD and SpA [3]. 
 
Using micro-CT scan after oral gavage with Gastrografin and a micro-Positron Emission 
Tomography  scan (PET)  after intravenous injection of 2-deoxy-2(17F)fluoro-d-glucose, we 
were able to illustrate and quantify inflammation in the terminal ileum and the joints in this 
animal model [4]. As such, this technique represents a very attractive tool to study therapeutic 
interventions (see figure 1). 
 
HLA-B27 transgenic rats 
The HLA-B27 transgenic rat model was created by microinjection of the human HLA-B27 
and β2-microglobulin genes into rat zygotes. By expressing HLA-B27 and β2-microglobulin, 
these rats develop spondylarthritis, inflammatory bowel disease (which mainly affects the 
colon), psoriasis vulgaris and genital inflammation [5]. 
 
Mechanism based future treatment modalities in IBD and SpA  
Two different approaches can be used to shape the fundaments for future treatment modalities 
in IBD and SpA. Firstly, the search for common susceptibility genes linking different human 
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immune mediated inflammatory diseases may help to identify potential common 
etiopathogenetic pathways leading to disease (see figure 2). Secondly, interventional studies 
in TNF
∆ARE
 mice and HLA-B27 transgenic rats will be useful to study the effect of potential 
therapeutics on both gut and joint inflammation. 
 
Common susceptibility genes and associated pathways 
CARD15, bacterial recognition and NFκB activation 
The first susceptibility gene that has been identified for CD is CARD15, also known as NOD2. 
Variants within this gene increase the risk for CD by threefold for heterozygous individuals 
and 33-44 fold for homozygous and compound heterozygous individuals. Several studies 
excluded an association between CARD15 variants and AS or  SpA in IBD populations [6-
11]. However an association was found in SpA patients between the carriage of CARD15 
variants and the development of chronic subclinical gut inflammation, with odds ratio’s of 2.9 
as compared to control population and of 5.8 as compared to SpA patients without gut 
inflammation [11]. Although CARD15 mutations do not seem to predispose to joint 
inflammation in SpA patients, it might confer a risk towards the development of (sub)clinical 
gut inflammation, rendering these patients more prone to develop overt IBD. In order to use 
such a marker to predict patient outcome, long-term follow-up studies are necessary.  
However, a CARD15-mediated NFκB-dependent inflammatory reaction might be an 
important pathogenic process within the joints [12]. In Blau syndrome, characterized by 
inflammatory arthritis, uveitis and dermatitis, a definite link was found with the carriage of 
mutations in the CARD15 gene. The protein is expressed in joint tissue, and bacterial cell wall 
components have been demonstrated in synovium of SpA patients, supporting the idea that 
CARD15 can locally trigger inflammation. It has been demonstrated that the activation of 
CARD15 in synovial fibroblasts from patients with reumatoid arthritis acts synergistically 
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with Toll like receptors in the production of pro-inflammatory and destructive mediators [13]. 
Finally , CARD15-deficient mice do not develop arthritis upon direct local challenge with 
peptidoglycan, whereas wild type mice do [14].  
 
The IL23/T helper 17 (Th17) axis  
A second important associated gene complex for IBD that has been identified through 
genome-wide association is the pathway leading to T helper 17 (Th17) cell development [15]. 
These T cells produce a specific cytokine pattern, specifically IL17A, IL17F, IL22, TNF-α 
and IL6. Differentiation of these TH17 cells is induced by TGFb and IL21, while the 
perpetuation of the Th17 cell program is mediated by IL23R signalling. Retinoic acid 
receptor-related orphan receptor gamma (ROR gamma), but also RORalpha was shown to 
regulate Th17 differentiation [16].  
Both protective and risk variants in the IL23R gene have been found associated with both CD 
and AS [17, 18]. Other variants in genes involved in IL23R signalling and Th17 
differentiation have been described in IBD (IL12B, STAT3, JAK2, and CCR6) but their 
relevance still needs to be studied in SpA.  
The functional consequence of genetic variants within the IL23/Th17 axis on the normal 
execution of this pathway is not well studied. A major draw-back is the low allele frequency 
of the associated variants, and therefore the lack of sufficiently large numbers of patients to be 
studied. Nevertheless, it is clear that in general Th17 effector cytokines are aberrantly 
expressed in affected tissues of patients with CD as well as of patients with AS. A specific 
expression signature of IL23 an IL17 has been found in patients with subclinical chronic gut 
inflammation: IL23 gene expression is increased in terminal ileum of AS patients, but unlike 
in CD, IL17 is not induced [19].  
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IL17 differentiation and effector cytokines are increased in intestinal mucosa of IBD patients 
and seems higher in active ulcerative colitis than Crohn colitis [20]. Intriguingly, the 
expression of Th17 differentiation factors in active Crohn ileitis is not changed as compared 
to healthy ileal tissue unless for the effector cytokines IL17 and IL22 (unpublished data).  
The role of IL17A/IL17F in intestinal inflammatory colitis may be dual: neutralisation of 
IL17A and/or IL17F in animal models of colitis leads to contradictory results [21, 22]. 
Together, these findings suggest that a neutralisation of Th17 effector cytokines as therapeutic 
target or a neutralisation of ROR gamma deserves attention, with possibly different effects in 
colonic and ileal inflammation. 
 
HLA-B27 and endoplasmic reticulum stress 
The most studied gene of interest for AS is the HLA-B27 gene. The association of HLA-B27 
with arthritis is found in 90% of patients with AS without IBD, 25-70% of patients with AS 
and IBD but only in 7% of patients with IBD and sacroiliitis and 7% of patients with IBD 
alone.  
In HLA-B27 expressing macrophages, IL23 was synergistically up-regulated in response to 
lipopolysaccharide stimulation [23]. In addition, IL23 and IL17 were strongly expressed in 
the colon of HLA-B27 transgenic rats 
The trimer heavy chain of HLA-B27 has a tendency to misfold in the endoplasmic reticulum 
(ER) and activate the unfolded protein response (UPR) which induces profound changes in 
the cellular metabolism [24]. One of these changes includes an inhibition of the translation 
and the transcription of molecular chaperone genes and results in a downstream inflammation 
[25].  
An important role for ER stress in IBD is emerging: association between variants in one of the 
key components of ER stress (XBP1) with CD and UC has been demonstrated. Moreover a 
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deletion of XBP1 in intraepithelial cells induces a spontaneous enteritis secondary to Paneth 
cell dysfunction and over-reactive epithelium to bacterial products and TNF-α [26]. 
We have recently provided additional evidence supporting a key role of ER stress in both gut 
and joint inflammation. A study of mucosal gene expression profiles in IBD and SpA patients 
revealed an aberrant expression of metallothioneins [27]. These are acute stress proteins able 
to alleviate oxidative-stress induced ER stress in cardiac disease [28-30]. A recent  association 
study in a cohort of 182 AS patients for SNP markers corresponding to 40 CD risk loci 
described by Barrett and colleagues  identified a common association with a  locus linked 
with ORMDL3 gene expression, a gene involved in protein folding and ER stress [31, 32]. 
 
Interventional studies in TNF
∆ARE
 mice 
Prolyl hydroxylase inhibitors 
Chronic inflammation is associated with increased consumption and disturbed delivery of 
oxygen, resulting in profound hypoxia at the site of inflammation [33]. 
Hypoxia-inducible factor-1 (HIF-1) is the master regulator of cellular responses to low 
oxygen levels. During hypoxia, HIF-1 is stabilized through inhibition of “oxygen-sensing” 
prolyl hydroxylases, resulting in an adaptive gene transcription programme, which is essential 
for both enterocyte and chrondrocyte cell function and cell survival [34]. We found that the 
prolyl hydroxylase inhibitor dimethyloxalylglycin (DMOG) protects intestinal epithelial cells 
against TNF-α-induced cell death through HIF-1-dependent repression of Fas-associated 
death domain protein (FADD), a critical adaptor protein in TNFR-1-mediated apoptosis [35]. 
This anti-apoptotic action at least in part contributes to a fast restoration of barrier function 
and dampening of the chronic intestinal inflammation in TNF
∆ARE
 mice treated with DMOG. 
However, DMOG was not effective in the concomitant arthritis of these mice, possibly 
because DMOG is a non-selective hydroxylase inhibitor which also disturbs proper collagen 
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formation through interference with collagen hydroxylases [36]. The development of more 
specific HIF-hydroxylase inhibitors is eagerly awaited.  
CD8αβ lymphocyte inhibitors 
Ileal inflammation is associated with a decline of potentially protective TCRαβCD8αα and 
TCRγδ lymphocytes early in the disease process and the predominance of TNF/IFN-γ 
producing CD8αβ lymphocytes in the epithelium [37]. Additionally, a decrease in IFN-γ + 
CD4 intraepithelial lymphocytes is found. The IFN-γ dependence of the TNF∆ARE model may 
be related to IFN-γ producing CD8αβ intraepithelial lymphocytes rather than Th1 CD4 T-
lymphocyte response. 
In the lamina propria (LP), a significant increased CD4/CD8αβ ratio is observed as compared 
with wild type mice [37]. Lamina propria CD4 lymphocytes are characterized by decreased 
expression of IFN-γ and increased expression of IL17 and IL10. CD8αβ lymphocytes from 
the LP of both normal and diseased animals highly express IFN-γ indicating a decreased Th1 
and increased Th17 CD4 T-cell response in the inflamed LP and the persistent capacity of LP 
CD8αβ lymphocytes for IFN-γ production. 
 
Selective TNFR1 inhibitors 
Signalling through TNFRI in synovial fibroblasts and intestinal myofibroblasts appeared to be 
sufficient to develop combined gut and joint inflammation in TNF
∆ARE
 mice, providing the 
first strong evidence for a common pathophysiologic mechanism and suggests that attenuation 
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Invariant natural killer T-cell (iNKT cell) activators 
Absence of invariant natural killer T-cells (iNKT cells) aggravates articular and ileal 
inflammation in TNF
∆ARE
 mice. Chronic dysregulated TNF-α production activates iNKT cells 
by influencing their cross-talk with dendritic cells and as such, induces a counter-regulatory 
mechanism for dampening TNF-α-driven inflammation [39]. Activators of iNKT cells may 
thus represent a promising therapy for immune-mediated inflammatory disease. 
 
Leukocyte homing inhibitors 
The selective recruitment of leukocytes from the circulation to the target tissues is controlled 
through the interaction of adhesion molecules and chemokine receptors with their 
corresponding ligands. Ileal inflammation is associated with an increased αEβ7 integrin 
expression in peripheral activated/memory intestinal-homing CD8αβ lymphocytes. A similar 
enrichment of T cells carrying β7 integrins was found in inflamed synovial tissue from 
patients with early SpA [40]. Genetic ablation of β7 integrin protects mice against ileitis 
whereas absence of chemokine/chemokine receptor pair CCL25/CCR9 has no influence on 
inflammation, supporting the idea that CCR9-independent pathways of T-lymphocyte 
recruitment to the ileum are responsible for lymphocyte accumulation and disease 
pathogenesis in CD8-dependent TNF-α-driven CD [37]. 
 
Selective kinase blockade 
Selective blockade of Jun N-terminal Kinase 2 (JNK2) and tumour progression locus 2 
(Tp12) kinase is associated with an improvement of enterocolitis, whereas blockade of 
p38/MAPK-activated protein kinase 2 (p38/MK2) increases intestinal inflammation [41].  
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Summary 
The advances in techniques to study genetic predisposition of complex diseases can 
significantly aid to understand associated disease manifestations such as arthropathy. In this 
way, previously unidentified pathways such as bacterial recognition and ER stress were linked 
with both IBD and SpA. Finally, an elegant way to study these processes and to test 
therapeutic potential is the use of the TNF
∆are
 and HLA-B27 transgenic models. 
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Figure 1: Assessment of intestinal and articular inflammation through non-invasive 
micro-PET/CT scanning, using FDG as a PET-tracer. 
A: mouse positioned for micro-PET/CT scan. B: CT-image after oral contrast (gastrografin) 
administration, allowing easy identification of the terminal ileum (arrow). 
C and D: Detailed CT-images of the terminal ileum of a 16-week old TNF
∆ARE
 mouse with 
(D) and without (C) PET-image overlay. Note the sharp delineated FDG hot spot at the level 
of the terminal ileum. E and F: Detailed CT-images of the knee joint of the same animal, with 
(F) and without (E) PET-image overlay. Note the presence of knee joint inflammation, 
visualized with FDG-PET. G: Pictures of H&E-stained terminal ileal sections of the same 
TNF
∆ARE
 mouse (right) and a healthy littermate (left). Note the presence of increased 
inflammatory cell infiltrations and disturbance of the villous architecture in the TNF
∆ARE
 
mouse. H: PET-signal quantification at the level of the terminal ileum of the same TNF
∆ARE
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Figure 2: Common pathways involved in joint- and gut inflammation. 
Apoptosis of intestinal epithelial cells leads to a barrier breakdown. CARD15 is a bacterial 
receptor in the gut involved in the triggering of NF−κΒ-mediated pro-inflammatory reaction. 
Th1 and Th17 responses are induced. Polymorphisms in the CARD15 gene and the IL23R 
gene may modulate this response. 
Inflammation is characterized by microvascular dysfunction and an increased influx of 
oxygen-demanding inflammatory cells releasing pro-inflammatory cytokines like TNFα, 
which increases epithelial apoptosis by binding to TNFRI. Resulting mucosal hypoxia also 
increases apoptosis of the intestinal epithelial cells and promotes the influx of intraluminal 
antigens into the lamina propria, which in turn sustains the inflammatory process. Induced 
endoplasmic reticulum stress further increases epithelial response to bacteriae and intensifies 
inflammatory reaction.  
Activated T cells and macrophages carrying bacterial components migrate to the joints and 
may be recognized by adhesion molecules such as b7 integrins and VAP-1. CARD15 may 
recognize bacterial components and induces NF-κB-dependent inflammation. The targeted 
joint mesenchymal cells become activated and sustain inflammation. Finally, circulation of 
iNKT cells dampens inflammation in gut and joints. 
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